MedTrace Logo

Dexmedetomidine for Continuous Sedation

NCT00226785 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2006-11-14

No results posted yet for this study

Summary

The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice sedation with propofol/midazolam and daily sedation stops, in maintaining a target depth of sedation in long-stay intensive care unit (ICU) patients, and that dexmedetomidine, compared with current best practice, reduces the length of ICU stay.

Conditions

  • Conscious Sedation

Interventions

DRUG

Dexmedetomidine

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    lead INDUSTRY

Principal Investigators

  • Jukka Takala, MD, PhD · University/University Hospital, Bern, Switzerland

  • Esko Ruokonen, MD, PhD · Kuopio University Hospital, Finland

  • Stephan Jakob, MD, PhD · University Hospital, Bern, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2006-07-31

Countries

  • Finland
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00226785 on ClinicalTrials.gov